APO Research
Talk to an analyst

APO RESEARCH · REPORT

Biologics CDMO

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Biologics CDMO Market Analysis and Forecast 2026-2032

30 December 2025196 pages

Choose your research edition.

Industry ResearchBiologics CDMO Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Biologics CDMO Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Biologics CDMO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biologics CDMO Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Biologics CDMO Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Biologics CDMO market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Biologics CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Biologics CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Biologics CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Biologics CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Biologics CDMO include AGC, Boehringer Ingelheim, Fujifilm Diosynth Biotechnologies, ICON Plc, Samsung Biologics, Toyobo, AbbVie, Lonza Group AG and Thermo Fisher Scientific, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Biologics CDMO, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Biologics CDMO, also provides the sales of main regions and countries. Of the upcoming market potential for Biologics CDMO, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Biologics CDMO sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Biologics CDMO market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Biologics CDMO sales, projected growth trends, production technology, application and end-user industry.

Biologics CDMO Segment by Company

AGC

Boehringer Ingelheim

Fujifilm Diosynth Biotechnologies

ICON Plc

Samsung Biologics

Toyobo

AbbVie

Lonza Group AG

Thermo Fisher Scientific

WuXi Biologics

Biologics CDMO Segment by Type

Biological Agent

Biosimilar Drug

Biologics CDMO Segment by Application

Cell Therapy

Drug Development

Others

Biologics CDMO Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologics CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biologics CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologics CDMO.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Biologics CDMO in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Biologics CDMO manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Biologics CDMO sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Biologics CDMO Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Biological Agent Major Manufacturers Table 3. Biosimilar Drug Major Manufacturers Table 4. Global Biologics CDMO Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Cell Therapy Major Manufacturers Table 6. Drug Development Major Manufacturers Table 7. Others Major Manufacturers Table 8. Biologics CDMO Industry Trends Table 9. Biologics CDMO Industry Drivers Table 10. Biologics CDMO Industry Opportunities and Challenges Table 11. Biologics CDMO Industry Restraints Table 12. Global Biologics CDMO Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 13. Global Biologics CDMO Revenue by Region (2021-2026) & (US$ Million) Table 14. Global Biologics CDMO Revenue by Region (2027-2032) & (US$ Million) Table 15. Global Biologics CDMO Revenue Market Share by Region (2021-2026) Table 16. Global Biologics CDMO Revenue Market Share by Region (2027-2032) Table 17. Global Biologics CDMO Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 18. Global Biologics CDMO Sales by Region (2021-2026) & (K Units) Table 19. Global Biologics CDMO Sales by Region (2027-2032) & (K Units) Table 20. Global Biologics CDMO Sales Market Share by Region (2021-2026) Table 21. Global Biologics CDMO Sales Market Share by Region (2027-2032) Table 22. Global Biologics CDMO Revenue by Manufacturers (US$ Million) & (2021-2026) Table 23. Global Biologics CDMO Revenue Market Share by Manufacturers (2021-2026) Table 24. Global Biologics CDMO Sales by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Biologics CDMO Sales Market Share by Manufacturers (2021-2026) Table 26. Global Biologics CDMO Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 27. Global Biologics CDMO Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 28. Global Biologics CDMO Key Manufacturers Manufacturing Sites & Headquarters Table 29. Global Biologics CDMO Manufacturers, Product Type & Application Table 30. Global Biologics CDMO Manufacturers' Establishment Date Table 31. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 32. Global Biologics CDMO by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 33. Global Biologics CDMO Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Biologics CDMO Revenue by Type (2021-2026) & (US$ Million) Table 35. Global Biologics CDMO Revenue by Type (2027-2032) & (US$ Million) Table 36. Global Biologics CDMO Revenue Market Share by Type (2021-2026) Table 37. Global Biologics CDMO Revenue Market Share by Type (2027-2032) Table 38. Global Biologics CDMO Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 39. Global Biologics CDMO Sales by Type (2021-2026) & (K Units) Table 40. Global Biologics CDMO Sales by Type (2027-2032) & (K Units) Table 41. Global Biologics CDMO Sales Market Share by Type (2021-2026) Table 42. Global Biologics CDMO Sales Market Share by Type (2027-2032) Table 43. Global Biologics CDMO Price by Type (2021-2026) & (US$/Unit) Table 44. Global Biologics CDMO Price by Type (2027-2032) & (US$/Unit) Table 45. Global Biologics CDMO Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 46. Global Biologics CDMO Revenue by Application (2021-2026) & (US$ Million) Table 47. Global Biologics CDMO Revenue by Application (2027-2032) & (US$ Million) Table 48. Global Biologics CDMO Revenue Market Share by Application (2021-2026) Table 49. Global Biologics CDMO Revenue Market Share by Application (2027-2032) Table 50. Global Biologics CDMO Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 51. Global Biologics CDMO Sales by Application (2021-2026) & (K Units) Table 52. Global Biologics CDMO Sales by Application (2027-2032) & (K Units) Table 53. Global Biologics CDMO Sales Market Share by Application (2021-2026) Table 54. Global Biologics CDMO Sales Market Share by Application (2027-2032) Table 55. Global Biologics CDMO Price by Application (2021-2026) & (US$/Unit) Table 56. Global Biologics CDMO Price by Application (2027-2032) & (US$/Unit) Table 57. AGC Company Information Table 58. AGC Business Overview Table 59. AGC Biologics CDMO Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 60. AGC Biologics CDMO Product Portfolio Table 61. AGC Recent Development Table 62. Boehringer Ingelheim Company Information Table 63. Boehringer Ingelheim Business Overview Table 64. Boehringer Ingelheim Biologics CDMO Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 65. Boehringer Ingelheim Biologics CDMO Product Portfolio Table 66. Boehringer Ingelheim Recent Development Table 67. Fujifilm Diosynth Biotechnologies Company Information Table 68. Fujifilm Diosynth Biotechnologies Business Overview Table 69. Fujifilm Diosynth Biotechnologies Biologics CDMO Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Fujifilm Diosynth Biotechnologies Biologics CDMO Product Portfolio Table 71. Fujifilm Diosynth Biotechnologies Recent Development Table 72. ICON Plc Company Information Table 73. ICON Plc Business Overview Table 74. ICON Plc Biologics CDMO Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. ICON Plc Biologics CDMO Product Portfolio Table 76. ICON Plc Recent Development Table 77. Samsung Biologics Company Information Table 78. Samsung Biologics Business Overview Table 79. Samsung Biologics Biologics CDMO Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Samsung Biologics Biologics CDMO Product Portfolio Table 81. Samsung Biologics Recent Development Table 82. Toyobo Company Information Table 83. Toyobo Business Overview Table 84. Toyobo Biologics CDMO Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Toyobo Biologics CDMO Product Portfolio Table 86. Toyobo Recent Development Table 87. AbbVie Company Information Table 88. AbbVie Business Overview Table 89. AbbVie Biologics CDMO Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. AbbVie Biologics CDMO Product Portfolio Table 91. AbbVie Recent Development Table 92. Lonza Group AG Company Information Table 93. Lonza Group AG Business Overview Table 94. Lonza Group AG Biologics CDMO Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Lonza Group AG Biologics CDMO Product Portfolio Table 96. Lonza Group AG Recent Development Table 97. Thermo Fisher Scientific Company Information Table 98. Thermo Fisher Scientific Business Overview Table 99. Thermo Fisher Scientific Biologics CDMO Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Thermo Fisher Scientific Biologics CDMO Product Portfolio Table 101. Thermo Fisher Scientific Recent Development Table 102. WuXi Biologics Company Information Table 103. WuXi Biologics Business Overview Table 104. WuXi Biologics Biologics CDMO Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. WuXi Biologics Biologics CDMO Product Portfolio Table 106. WuXi Biologics Recent Development Table 107. North America Biologics CDMO Revenue by Type (2021-2026) & (US$ Million) Table 108. North America Biologics CDMO Revenue by Type (2027-2032) & (US$ Million) Table 109. North America Biologics CDMO Sales by Type (2021-2026) & (K Units) Table 110. North America Biologics CDMO Sales by Type (2027-2032) & (K Units) Table 111. North America Biologics CDMO Sales Price by Type (2021-2026) & (US$/Unit) Table 112. North America Biologics CDMO Sales Price by Type (2027-2032) & (US$/Unit) Table 113. North America Biologics CDMO Revenue by Application (2021-2026) & (US$ Million) Table 114. North America Biologics CDMO Revenue by Application (2027-2032) & (US$ Million) Table 115. North America Biologics CDMO Sales by Application (2021-2026) & (K Units) Table 116. North America Biologics CDMO Sales by Application (2027-2032) & (K Units) Table 117. North America Biologics CDMO Sales Price by Application (2021-2026) & (US$/Unit) Table 118. North America Biologics CDMO Sales Price by Application (2027-2032) & (US$/Unit) Table 119. North America Biologics CDMO Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 120. North America Biologics CDMO Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 121. North America Biologics CDMO Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 122. North America Biologics CDMO Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 123. North America Biologics CDMO Sales by Country (2021-2026) & (K Units) Table 124. North America Biologics CDMO Sales by Country (2027-2032) & (K Units) Table 125. North America Biologics CDMO Sales Price by Country (2021-2026) & (US$/Unit) Table 126. North America Biologics CDMO Sales Price by Country (2027-2032) & (US$/Unit) Table 127. United States Biologics CDMO Revenue (2021-2032) & (US$ Million) Table 128. Canada Biologics CDMO Revenue (2021-2032) & (US$ Million) Table 129. Europe Biologics CDMO Revenue by Type (2021-2026) & (US$ Million) Table 130. Europe Biologics CDMO Revenue by Type (2027-2032) & (US$ Million) Table 131. Europe Biologics CDMO Sales by Type (2021-2026) & (K Units) Table 132. Europe Biologics CDMO Sales by Type (2027-2032) & (K Units) Table 133. Europe Biologics CDMO Sales Price by Type (2021-2026) & (US$/Unit) Table 134. Europe Biologics CDMO Sales Price by Type (2027-2032) & (US$/Unit) Table 135. Europe Biologics CDMO Revenue by Application (2021-2026) & (US$ Million) Table 136. Europe Biologics CDMO Revenue by Application (2027-2032) & (US$ Million) Table 137. Europe Biologics CDMO Sales by Application (2021-2026) & (K Units) Table 138. Europe Biologics CDMO Sales by Application (2027-2032) & (K Units) Table 139. Europe Biologics CDMO Sales Price by Application (2021-2026) & (US$/Unit) Table 140. Europe Biologics CDMO Sales Price by Application (2027-2032) & (US$/Unit) Table 141. Europe Biologics CDMO Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 142. Europe Biologics CDMO Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 143. Europe Biologics CDMO Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 144. Europe Biologics CDMO Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 145. Europe Biologics CDMO Sales by Country (2021-2026) & (K Units) Table 146. Europe Biologics CDMO Sales by Country (2027-2032) & (K Units) Table 147. Europe Biologics CDMO Sales Price by Country (2021-2026) & (US$/Unit) Table 148. Europe Biologics CDMO Sales Price by Country (2027-2032) & (US$/Unit) Table 149. Germany Biologics CDMO Revenue (2021-2032) & (US$ Million) Table 150. France Biologics CDMO Revenue (2021-2032) & (US$ Million) Table 151. U.K. Biologics CDMO Revenue (2021-2032) & (US$ Million) Table 152. Italy Biologics CDMO Revenue (2021-2032) & (US$ Million) Table 153. Netherlands Biologics CDMO Revenue (2021-2032) & (US$ Million) Table 154. China Biologics CDMO Revenue by Type (2021-2026) & (US$ Million) Table 155. China Biologics CDMO Revenue by Type (2027-2032) & (US$ Million) Table 156. China Biologics CDMO Sales by Type (2021-2026) & (K Units) Table 157. China Biologics CDMO Sales by Type (2027-2032) & (K Units) Table 158. China Biologics CDMO Sales Price by Type (2021-2026) & (US$/Unit) Table 159. China Biologics CDMO Sales Price by Type (2027-2032) & (US$/Unit) Table 160. China Biologics CDMO Revenue by Application (2021-2026) & (US$ Million) Table 161. China Biologics CDMO Revenue by Application (2027-2032) & (US$ Million) Table 162. China Biologics CDMO Sales by Application (2021-2026) & (K Units) Table 163. China Biologics CDMO Sales by Application (2027-2032) & (K Units) Table 164. China Biologics CDMO Sales Price by Application (2021-2026) & (US$/Unit) Table 165. China Biologics CDMO Sales Price by Application (2027-2032) & (US$/Unit) Table 166. Asia Biologics CDMO Revenue by Type (2021-2026) & (US$ Million) Table 167. Asia Biologics CDMO Revenue by Type (2027-2032) & (US$ Million) Table 168. Asia Biologics CDMO Sales by Type (2021-2026) & (K Units) Table 169. Asia Biologics CDMO Sales by Type (2027-2032) & (K Units) Table 170. Asia Biologics CDMO Sales Price by Type (2021-2026) & (US$/Unit) Table 171. Asia Biologics CDMO Sales Price by Type (2027-2032) & (US$/Unit) Table 172. Asia Biologics CDMO Revenue by Application (2021-2026) & (US$ Million) Table 173. Asia Biologics CDMO Revenue by Application (2027-2032) & (US$ Million) Table 174. Asia Biologics CDMO Sales by Application (2021-2026) & (K Units) Table 175. Asia Biologics CDMO Sales by Application (2027-2032) & (K Units) Table 176. Asia Biologics CDMO Sales Price by Application (2021-2026) & (US$/Unit) Table 177. Asia Biologics CDMO Sales Price by Application (2027-2032) & (US$/Unit) Table 178. Asia Biologics CDMO Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 179. Asia Biologics CDMO Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 180. Asia Biologics CDMO Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 181. Asia Biologics CDMO Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 182. Asia Biologics CDMO Sales by Country (2021-2026) & (K Units) Table 183. Asia Biologics CDMO Sales by Country (2027-2032) & (K Units) Table 184. Asia Biologics CDMO Sales Price by Country (2021-2026) & (US$/Unit) Table 185. Asia Biologics CDMO Sales Price by Country (2027-2032) & (US$/Unit) Table 186. Japan Biologics CDMO Revenue (2021-2032) & (US$ Million) Table 187. South Korea Biologics CDMO Revenue (2021-2032) & (US$ Million) Table 188. India Biologics CDMO Revenue (2021-2032) & (US$ Million) Table 189. Australia Biologics CDMO Revenue (2021-2032) & (US$ Million) Table 190. China Taiwan Biologics CDMO Revenue (2021-2032) & (US$ Million) Table 191. Southeast Asia Biologics CDMO Revenue (2021-2032) & (US$ Million) Table 192. SAMEA Biologics CDMO Revenue by Type (2021-2026) & (US$ Million) Table 193. SAMEA Biologics CDMO Revenue by Type (2027-2032) & (US$ Million) Table 194. SAMEA Biologics CDMO Sales by Type (2021-2026) & (K Units) Table 195. SAMEA Biologics CDMO Sales by Type (2027-2032) & (K Units) Table 196. SAMEA Biologics CDMO Sales Price by Type (2021-2026) & (US$/Unit) Table 197. SAMEA Biologics CDMO Sales Price by Type (2027-2032) & (US$/Unit) Table 198. SAMEA Biologics CDMO Revenue by Application (2021-2026) & (US$ Million) Table 199. SAMEA Biologics CDMO Revenue by Application (2027-2032) & (US$ Million) Table 200. SAMEA Biologics CDMO Sales by Application (2021-2026) & (K Units) Table 201. SAMEA Biologics CDMO Sales by Application (2027-2032) & (K Units) Table 202. SAMEA Biologics CDMO Sales Price by Application (2021-2026) & (US$/Unit) Table 203. SAMEA Biologics CDMO Sales Price by Application (2027-2032) & (US$/Unit) Table 204. SAMEA Biologics CDMO Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 205. SAMEA Biologics CDMO Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 206. SAMEA Biologics CDMO Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 207. SAMEA Biologics CDMO Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 208. SAMEA Biologics CDMO Sales by Country (2021-2026) & (K Units) Table 209. SAMEA Biologics CDMO Sales by Country (2027-2032) & (K Units) Table 210. SAMEA Biologics CDMO Sales Price by Country (2021-2026) & (US$/Unit) Table 211. SAMEA Biologics CDMO Sales Price by Country (2027-2032) & (US$/Unit) Table 212. Brazil Biologics CDMO Revenue (2021-2032) & (US$ Million) Table 213. Argentina Biologics CDMO Revenue (2021-2032) & (US$ Million) Table 214. Chile Biologics CDMO Revenue (2021-2032) & (US$ Million) Table 215. Colombia Biologics CDMO Revenue (2021-2032) & (US$ Million) Table 216. Peru Biologics CDMO Revenue (2021-2032) & (US$ Million) Table 217. Saudi Arabia Biologics CDMO Revenue (2021-2032) & (US$ Million) Table 218. Israel Biologics CDMO Revenue (2021-2032) & (US$ Million) Table 219. UAE Biologics CDMO Revenue (2021-2032) & (US$ Million) Table 220. Turkey Biologics CDMO Revenue (2021-2032) & (US$ Million) Table 221. Iran Biologics CDMO Revenue (2021-2032) & (US$ Million) Table 222. Egypt Biologics CDMO Revenue (2021-2032) & (US$ Million) Table 223. Key Raw Materials Table 224. Raw Materials Key Suppliers Table 225. Biologics CDMO Distributors List Table 226. Biologics CDMO Customers List Table 227. Research Programs/Design for This Report Table 228. Authors List of This Report Table 229. Secondary Sources Table 230. Primary Sources List of Figures Figure 1. Biologics CDMO Image Figure 2. Global Biologics CDMO Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Biologics CDMO Market Size Share 2021 VS 2025 VS 2032 Figure 4. Biological Agent Image Figure 5. Biosimilar Drug Image Figure 6. Global Biologics CDMO Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Biologics CDMO Market Size Share 2021 VS 2025 VS 2032 Figure 8. Cell Therapy Image Figure 9. Drug Development Image Figure 10. Others Image Figure 11. Global Biologics CDMO Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Biologics CDMO Revenue (2021-2032) & (US$ Million) Figure 13. Global Biologics CDMO Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 14. Global Biologics CDMO Revenue Market Share by Region: 2025 Versus 2032 Figure 15. Global Biologics CDMO Revenue Market Share by Region (2021-2032) Figure 16. Global Biologics CDMO Sales (2021-2032) & (K Units) Figure 17. Global Biologics CDMO Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 18. Global Biologics CDMO Sales Market Share by Region (2021-2032) Figure 19. US & Canada & Mexico Biologics CDMO Sales YoY (2021-2032) & (K Units) Figure 20. Europe Biologics CDMO Sales YoY (2021-2032) & (K Units) Figure 21. China Biologics CDMO Sales YoY (2021-2032) & (K Units) Figure 22. Asia (Excluding China) Biologics CDMO Sales YoY (2021-2032) & (K Units) Figure 23. South America, Middle East and Africa Biologics CDMO Sales YoY (2021-2032) & (K Units) Figure 24. Global Biologics CDMO Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 25. Global Biologics CDMO Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 26. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Global Biologics CDMO Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Biologics CDMO Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 29. Global Biologics CDMO Revenue Market Share by Type (2021-2032) Figure 30. Global Biologics CDMO Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 31. Global Biologics CDMO Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Biologics CDMO Sales Market Share by Type (2021-2032) Figure 33. Global Biologics CDMO Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 34. Global Biologics CDMO Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 35. Global Biologics CDMO Revenue Market Share by Application (2021-2032) Figure 36. Global Biologics CDMO Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 37. Global Biologics CDMO Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Biologics CDMO Sales Market Share by Application (2021-2032) Figure 39. North America Biologics CDMO Revenue Share by Type (2021-2032) Figure 40. North America Biologics CDMO Sales Share by Type (2021-2032) Figure 41. North America Biologics CDMO Revenue Share by Application (2021-2032) Figure 42. North America Biologics CDMO Sales Share by Application (2021-2032) Figure 43. North America Biologics CDMO Revenue Share by Country (2021-2032) Figure 44. North America Biologics CDMO Sales Share by Country (2021-2032) Figure 45. Europe Biologics CDMO Revenue Share by Type (2021-2032) Figure 46. Europe Biologics CDMO Sales Share by Type (2021-2032) Figure 47. Europe Biologics CDMO Revenue Share by Application (2021-2032) Figure 48. Europe Biologics CDMO Sales Share by Application (2021-2032) Figure 49. Europe Biologics CDMO Revenue Share by Country (2021-2032) Figure 50. Europe Biologics CDMO Sales Share by Country (2021-2032) Figure 51. China Biologics CDMO Revenue Share by Type (2021-2032) Figure 52. China Biologics CDMO Sales Share by Type (2021-2032) Figure 53. China Biologics CDMO Revenue Share by Application (2021-2032) Figure 54. China Biologics CDMO Sales Share by Application (2021-2032) Figure 55. Asia Biologics CDMO Revenue Share by Type (2021-2032) Figure 56. Asia Biologics CDMO Sales Share by Type (2021-2032) Figure 57. Asia Biologics CDMO Revenue Share by Application (2021-2032) Figure 58. Asia Biologics CDMO Sales Share by Application (2021-2032) Figure 59. Asia Biologics CDMO Revenue Share by Country (2021-2032) Figure 60. Asia Biologics CDMO Sales Share by Country (2021-2032) Figure 61. SAMEA Biologics CDMO Revenue Share by Type (2021-2032) Figure 62. SAMEA Biologics CDMO Sales Share by Type (2021-2032) Figure 63. SAMEA Biologics CDMO Revenue Share by Application (2021-2032) Figure 64. SAMEA Biologics CDMO Sales Share by Application (2021-2032) Figure 65. SAMEA Biologics CDMO Revenue Share by Country (2021-2032) Figure 66. SAMEA Biologics CDMO Sales Share by Country (2021-2032) Figure 67. Biologics CDMO Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Biologics CDMO Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Biological Agent
  • Biosimilar Drug
Applications
  • Cell Therapy
  • Drug Development
  • Others
Companies covered
  • AGC
  • Boehringer Ingelheim
  • Fujifilm Diosynth Biotechnologies
  • ICON Plc
  • Samsung Biologics
  • Toyobo
  • AbbVie
  • Lonza Group AG
  • Thermo Fisher Scientific
  • WuXi Biologics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Biologics CDMO Market by Type
  3. 1.2.1 Global Biologics CDMO Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Biological Agent
  5. 1.2.3 Biosimilar Drug
  6. 1.3 Biologics CDMO Market by Application
  7. 1.3.1 Global Biologics CDMO Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Cell Therapy
  9. 1.3.3 Drug Development
  10. 1.3.4 Others
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Biologics CDMO Market Dynamics
  1. 2.1 Biologics CDMO Industry Trends
  2. 2.2 Biologics CDMO Industry Drivers
  3. 2.3 Biologics CDMO Industry Opportunities and Challenges
  4. 2.4 Biologics CDMO Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Biologics CDMO Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Biologics CDMO Revenue by Region
  3. 3.2.1 Global Biologics CDMO Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Biologics CDMO Revenue by Region (2021-2026)
  5. 3.2.3 Global Biologics CDMO Revenue by Region (2027-2032)
  6. 3.2.4 Global Biologics CDMO Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Biologics CDMO Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Biologics CDMO Sales by Region
  9. 3.4.1 Global Biologics CDMO Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Biologics CDMO Sales by Region (2021-2026)
  11. 3.4.3 Global Biologics CDMO Sales by Region (2027-2032)
  12. 3.4.4 Global Biologics CDMO Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Biologics CDMO Revenue by Manufacturers
  2. 4.1.1 Global Biologics CDMO Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Biologics CDMO Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Biologics CDMO Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Biologics CDMO Sales by Manufacturers
  6. 4.2.1 Global Biologics CDMO Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Biologics CDMO Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Biologics CDMO Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Biologics CDMO Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Biologics CDMO Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Biologics CDMO Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Biologics CDMO Manufacturers, Product Type & Application
  13. 4.7 Global Biologics CDMO Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Biologics CDMO Market CR5 and HHI
  16. 4.8.2 2025 Biologics CDMO Tier 1, Tier 2, and Tier 3
5 Biologics CDMO Market by Type
  1. 5.1 Global Biologics CDMO Revenue by Type
  2. 5.1.1 Global Biologics CDMO Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Biologics CDMO Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Biologics CDMO Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Biologics CDMO Sales by Type
  6. 5.2.1 Global Biologics CDMO Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Biologics CDMO Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Biologics CDMO Sales Market Share by Type (2021-2032)
  9. 5.3 Global Biologics CDMO Price by Type
6 Biologics CDMO Market by Application
  1. 6.1 Global Biologics CDMO Revenue by Application
  2. 6.1.1 Global Biologics CDMO Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Biologics CDMO Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Biologics CDMO Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Biologics CDMO Sales by Application
  6. 6.2.1 Global Biologics CDMO Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Biologics CDMO Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Biologics CDMO Sales Market Share by Application (2021-2032)
  9. 6.3 Global Biologics CDMO Price by Application
7 Company Profiles
  1. 7.1 AGC
  2. 7.1.1 AGC Company Information
  3. 7.1.2 AGC Business Overview
  4. 7.1.3 AGC Biologics CDMO Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 AGC Biologics CDMO Product Portfolio
  6. 7.1.5 AGC Recent Developments
  7. 7.2 Boehringer Ingelheim
  8. 7.2.1 Boehringer Ingelheim Company Information
  9. 7.2.2 Boehringer Ingelheim Business Overview
  10. 7.2.3 Boehringer Ingelheim Biologics CDMO Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Boehringer Ingelheim Biologics CDMO Product Portfolio
  12. 7.2.5 Boehringer Ingelheim Recent Developments
  13. 7.3 Fujifilm Diosynth Biotechnologies
  14. 7.3.1 Fujifilm Diosynth Biotechnologies Company Information
  15. 7.3.2 Fujifilm Diosynth Biotechnologies Business Overview
  16. 7.3.3 Fujifilm Diosynth Biotechnologies Biologics CDMO Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Fujifilm Diosynth Biotechnologies Biologics CDMO Product Portfolio
  18. 7.3.5 Fujifilm Diosynth Biotechnologies Recent Developments
  19. 7.4 ICON Plc
  20. 7.4.1 ICON Plc Company Information
  21. 7.4.2 ICON Plc Business Overview
  22. 7.4.3 ICON Plc Biologics CDMO Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 ICON Plc Biologics CDMO Product Portfolio
  24. 7.4.5 ICON Plc Recent Developments
  25. 7.5 Samsung Biologics
  26. 7.5.1 Samsung Biologics Company Information
  27. 7.5.2 Samsung Biologics Business Overview
  28. 7.5.3 Samsung Biologics Biologics CDMO Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Samsung Biologics Biologics CDMO Product Portfolio
  30. 7.5.5 Samsung Biologics Recent Developments
  31. 7.6 Toyobo
  32. 7.6.1 Toyobo Company Information
  33. 7.6.2 Toyobo Business Overview
  34. 7.6.3 Toyobo Biologics CDMO Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Toyobo Biologics CDMO Product Portfolio
  36. 7.6.5 Toyobo Recent Developments
  37. 7.7 AbbVie
  38. 7.7.1 AbbVie Company Information
  39. 7.7.2 AbbVie Business Overview
  40. 7.7.3 AbbVie Biologics CDMO Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 AbbVie Biologics CDMO Product Portfolio
  42. 7.7.5 AbbVie Recent Developments
  43. 7.8 Lonza Group AG
  44. 7.8.1 Lonza Group AG Company Information
  45. 7.8.2 Lonza Group AG Business Overview
  46. 7.8.3 Lonza Group AG Biologics CDMO Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Lonza Group AG Biologics CDMO Product Portfolio
  48. 7.8.5 Lonza Group AG Recent Developments
  49. 7.9 Thermo Fisher Scientific
  50. 7.9.1 Thermo Fisher Scientific Company Information
  51. 7.9.2 Thermo Fisher Scientific Business Overview
  52. 7.9.3 Thermo Fisher Scientific Biologics CDMO Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Thermo Fisher Scientific Biologics CDMO Product Portfolio
  54. 7.9.5 Thermo Fisher Scientific Recent Developments
  55. 7.10 WuXi Biologics
  56. 7.10.1 WuXi Biologics Company Information
  57. 7.10.2 WuXi Biologics Business Overview
  58. 7.10.3 WuXi Biologics Biologics CDMO Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 WuXi Biologics Biologics CDMO Product Portfolio
  60. 7.10.5 WuXi Biologics Recent Developments
8 North America
  1. 8.1 North America Biologics CDMO Market Size by Type
  2. 8.1.1 North America Biologics CDMO Revenue by Type (2021-2032)
  3. 8.1.2 North America Biologics CDMO Sales by Type (2021-2032)
  4. 8.1.3 North America Biologics CDMO Price by Type (2021-2032)
  5. 8.2 North America Biologics CDMO Market Size by Application
  6. 8.2.1 North America Biologics CDMO Revenue by Application (2021-2032)
  7. 8.2.2 North America Biologics CDMO Sales by Application (2021-2032)
  8. 8.2.3 North America Biologics CDMO Price by Application (2021-2032)
  9. 8.3 North America Biologics CDMO Market Size by Country
  10. 8.3.1 North America Biologics CDMO Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Biologics CDMO Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Biologics CDMO Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Biologics CDMO Market Size by Type
  2. 9.1.1 Europe Biologics CDMO Revenue by Type (2021-2032)
  3. 9.1.2 Europe Biologics CDMO Sales by Type (2021-2032)
  4. 9.1.3 Europe Biologics CDMO Price by Type (2021-2032)
  5. 9.2 Europe Biologics CDMO Market Size by Application
  6. 9.2.1 Europe Biologics CDMO Revenue by Application (2021-2032)
  7. 9.2.2 Europe Biologics CDMO Sales by Application (2021-2032)
  8. 9.2.3 Europe Biologics CDMO Price by Application (2021-2032)
  9. 9.3 Europe Biologics CDMO Market Size by Country
  10. 9.3.1 Europe Biologics CDMO Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Biologics CDMO Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Biologics CDMO Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
10 China
  1. 10.1 China Biologics CDMO Market Size by Type
  2. 10.1.1 China Biologics CDMO Revenue by Type (2021-2032)
  3. 10.1.2 China Biologics CDMO Sales by Type (2021-2032)
  4. 10.1.3 China Biologics CDMO Price by Type (2021-2032)
  5. 10.2 China Biologics CDMO Market Size by Application
  6. 10.2.1 China Biologics CDMO Revenue by Application (2021-2032)
  7. 10.2.2 China Biologics CDMO Sales by Application (2021-2032)
  8. 10.2.3 China Biologics CDMO Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Biologics CDMO Market Size by Type
  2. 11.1.1 Asia Biologics CDMO Revenue by Type (2021-2032)
  3. 11.1.2 Asia Biologics CDMO Sales by Type (2021-2032)
  4. 11.1.3 Asia Biologics CDMO Price by Type (2021-2032)
  5. 11.2 Asia Biologics CDMO Market Size by Application
  6. 11.2.1 Asia Biologics CDMO Revenue by Application (2021-2032)
  7. 11.2.2 Asia Biologics CDMO Sales by Application (2021-2032)
  8. 11.2.3 Asia Biologics CDMO Price by Application (2021-2032)
  9. 11.3 Asia Biologics CDMO Market Size by Country
  10. 11.3.1 Asia Biologics CDMO Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Biologics CDMO Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Biologics CDMO Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Biologics CDMO Market Size by Type
  2. 12.1.1 SAMEA Biologics CDMO Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Biologics CDMO Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Biologics CDMO Price by Type (2021-2032)
  5. 12.2 SAMEA Biologics CDMO Market Size by Application
  6. 12.2.1 SAMEA Biologics CDMO Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Biologics CDMO Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Biologics CDMO Price by Application (2021-2032)
  9. 12.3 SAMEA Biologics CDMO Market Size by Country
  10. 12.3.1 SAMEA Biologics CDMO Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Biologics CDMO Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Biologics CDMO Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Biologics CDMO Value Chain Analysis
  2. 13.1.1 Biologics CDMO Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Biologics CDMO Production Mode & Process
  6. 13.2 Biologics CDMO Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Biologics CDMO Distributors
  9. 13.2.3 Biologics CDMO Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst